MARKET

OBLN

OBLN

Obalon
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.020
-0.330
-14.04%
Pre Market: 2.090 +0.07 +3.47% 08:47 05/07 EDT
OPEN
2.350
PREV CLOSE
2.350
HIGH
2.409
LOW
1.950
VOLUME
1.59K
TURNOVER
--
52 WEEK HIGH
10.77
52 WEEK LOW
0.6600
MARKET CAP
20.24M
P/E (TTM)
-1.2662
1D
5D
1M
3M
1Y
5Y
8-K: OBALON THERAPEUTICS INC
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 2d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 2d ago
Intragastric Balloon Market | End User Analysis Focus on Key Players, Size, Trends, Growth Opportunities and Forecast To 2031
May 04, 2021 (WiredRelease via Comtex) -- The latest research report provides a complete assessment of the Global Intragastric Balloon market for the...
marketresearch.biz · 3d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 04/30 12:14
Intragastric Balloon Market Size in APAC will surpass revenue collection of USD 13 Million
Apr 27, 2021 (Market Insight Reports) -- The Asia Pacific intragastric balloon market size provides an in-depth analysis on this industry with accurate...
Market Insight Reports · 04/27 11:34
Intragastric Balloon Market Insights, Global Research and Clinical Survey Report 2021-2026
Apr 27, 2021 (Market Insight Reports) -- The Global Intragastric Balloon Market Research Report Forecast 2021 - 2026 The Report begins with an overview of...
Market Insight Reports · 04/27 07:49
Netflix, The Middleby among premarket losers' pack
Digital Ally (DGLY) -13%.Netflix (NFLX) -8% on Q1 earnings release.Lions Gate Entertainment (LGF-A) -8%.Obalon Therapeutics (OBLN) -6%.The Middleby (MIDD) -6% after Welbilt to be acquired by The Middleby Corp in an all-stock
Seekingalpha · 04/21 12:22
Intragastric Balloon Market Trends- Industry Analysis, Share, Growth, Product, Top Key Players and Forecast 2028
Apr 21, 2021 (Market Insight Reports) -- Selbyville, Delaware According to the business intelligence report titled 'GLOBAL Intragastric Balloon Market...
Market Insight Reports · 04/21 05:40
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OBLN. Analyze the recent business situations of Obalon through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OBLN stock price target is 6.15 with a high estimate of 6.15 and a low estimate of 6.15.
EPS
Institutional Holdings
Institutions: 39
Institutional Holdings: 2.22M
% Owned: 22.16%
Shares Outstanding: 10.02M
TypeInstitutionsShares
Increased
4
438.72K
New
4
105.45K
Decreased
2
747.22K
Sold Out
2
192.89K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.50%
Healthcare Equipment & Supplies
-0.26%
Key Executives
Non-Executive Chairman/Independent Director
Kim Kamdar
President/Chief Executive Officer/Director
Andrew Rasdal
Chief Financial Officer
Nooshin Hussainy
Vice President
Donald Young
Other
Robert MacDonald
Vice President
Todd Wood
Director
William Plovanic
Independent Director
Raymond Dittamore
Independent Director
Douglas Fisher
Independent Director
Lesley Howe
Independent Director
Sharon Stevenson
Other
Bob MacDonald
No Data
  • All
  • Financials
  • Insiders
More
About OBLN
Obalon Therapeutics, Inc. is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.

Webull offers kinds of Obalon Therapeutics Inc stock information, including NASDAQ:OBLN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OBLN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OBLN stock methods without spending real money on the virtual paper trading platform.